ArticleNature communications2025
DrBioRight 2.0: an LLM-powered bioinformatics chatbot for large-scale cancer functional proteomics analysis.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- MetaboAnnotate: An AI-powered Multiagent Framework for Integrating Annotation Tools for Untargeted Metabolomics.Analytical chemistry · 2026Article
- i-gRINN: a next-generation web server for protein energy network analysis of heterogeneous biomolecular systems with natural language-based data exploration.Nucleic acids research · 2026Article
- GeneGenie: enhancing biomedical question-answering with agentic graphs.Briefings in bioinformatics · 2026Article
- Review
- Article
- Protein foundation models: a comprehensive survey.Science China. Life sciences · 2026Review
- Large language model agents for biological intelligence across genomics, proteomics, spatial biology, and biomedicine.Briefings in bioinformatics · 2026Review
- Multimodal AI agents for capturing and sharing proteomics laboratory practice.Molecular systems biology · 2026Article
- DermaGPT a federated multimodal framework with a meta learned trust function for interpretable dermatology diagnostics.Scientific reports · 2026Article
- Evaluating reasoning large language models with human-like thinking in ophthalmic question answering.BMJ open ophthalmology · 2026Article
- SomaMutDB 2.0: A comprehensive database for exploring somatic mutations and their functional impact in normal human tissues.Nucleic acids research · 2026Article
- CellMiner cross-database (CellMinerCDB) version 2.2 for explorations of patient-derived cancer cell line pharmacogenomics.Nucleic acids research · 2026Article
- REDAC: RNA-seq expression data analysis chatbot.Bioinformatics advances · 2026Article
- DeepPGDB: A novel paradigm for AI-guided interactive plant genomic database.Plant communications · 2025Article
- Prompt-based bioinformatics: a new interface for multi-omics analysis.Nature reviews. Genetics · 2025Article
- A large language model for deriving spectral embeddings for accurate compound identification in mass spectrometry.Communications chemistry · 2025Article
- The rise and potential opportunities of large language model agents in bioinformatics and biomedicine.Briefings in bioinformatics · 2025Review
- DrugBERT: a BERT-based approach integrating LDA topic embedding and efficacy-aware mechanism for predicting anti-tumor drug efficacy.Journal of translational medicine · 2025Article
- The potential of large language models to advance precision oncology.EBioMedicine · 2025Review
- Multiple Confabulations Found in Bioinformatics Tasks Carried Out by Several Free Large Language Models.Current genomics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Functional proteomics provides critical insights into cancer mechanisms, facilitating the discovery of novel biomarkers and therapeutic targets. We have developed a comprehensive cancer functional proteomics resource using reverse phase protein arrays, incorporating data from nearly 8000 patient samples from The Cancer Genome Atlas and approximately 900 samples from the Cancer Cell Line Encyclopedia. Our dataset includes a curated panel of nearly 500 high-quality antibodies, covering all major cancer hallmark pathways. To enhance the accessibility and analytic power of this resource, we introduce DrBioRight 2.0 ( https://drbioright.org ), an intuitive bioinformatic platform powered by state-of-the-art large language models. DrBioRight enables researchers to explore protein-centric cancer omics data, perform advanced analyses, visualize results, and engage in interactive discussions using natural language. By streamlining complex proteogenomic analyses, this tool accelerates the translation of large-scale functional proteomics data into meaningful biomedical insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.